Treatment of Chagas Disease from CDC
The two drugs used to treat infection with Trypanosoma cruzi are nifurtimox and benznidazole. In the United States, these drugs are not FDA approved and are available only from CDC under investigational protocols. For both drugs, side effects are fairly common, and tend to be more frequent and more severe with increasing age.
Common side effects of benznidazole treatment include:
- allergic dermatitis
- peripheral neuropathy
- anorexia and weight loss
- insomnia
The most common side effects of nifurtimox are:
- anorexia and weight loss
- polyneuropathy
- nausea
- vomiting
- headache
- dizziness or vertigo
Contraindications for treatment include severe hepatic and/or renal disease. As safety for infants exposed through breastfeeding has not been documented, withholding treatment while breastfeeding is also recommended. The following table outlines recommended dosage regimens by age group:
Drug | Age group | Dosage and duration |
---|---|---|
Benznidazole | < 12 years | 5-7.5 mg/kg per day orally in 2 divided doses for 60 days |
12 years or older | 5-7 mg/kg per day orally in 2 divided doses for 60 days | |
Nifurtimox | ≤ 10 years | 15-20 mg/kg per day orally in 3 or 4 divided doses for 90 days |
11-16 years | 12.5-15 mg/kg per day orally in 3 or 4 divided doses for 90 days | |
17 years or older | 8-10 mg/kg per day orally in 3 or 4 divided doses for 90 days |
Questions regarding treatment should be directed to Parasitic Diseases Public Inquiries (404-718-4745; e-mail chagas@cdc.gov).
For emergencies (for example, acute Chagas disease with severe manifestations, Chagas disease in a newborn, or Chagas disease in an immunocompromised person) outside of regular business hours, call the CDC Emergency Operations Center (770-488-7100) and ask for the person on call for Parasitic Diseases.